目的了解新生儿重症监护室(the neonatal in-tensive care unit,NICU)足月新生儿入院24h内血清白蛋白浓度改变情况与新生儿危重病例评分及预后的关系。方法测定71例足月新生儿入院24h内血清白蛋白浓度,把血清白蛋白浓度分为<35g/L、3...目的了解新生儿重症监护室(the neonatal in-tensive care unit,NICU)足月新生儿入院24h内血清白蛋白浓度改变情况与新生儿危重病例评分及预后的关系。方法测定71例足月新生儿入院24h内血清白蛋白浓度,把血清白蛋白浓度分为<35g/L、35～50g/L2组,分析血清白蛋白浓度与新生儿危重病例评分及预后的关系。结果血清白蛋白浓度异常与预后有关,血清白蛋白浓度<35g/L组新生儿危重病例评分比正常组低、死亡人数百分比比正常组高,住院时间长。结论低血清白蛋白浓度与足月新生儿的预后有重要相关性。展开更多
感染性休克在重症患者中占有相当大的比率，也是重症病房主要死亡的原因。因此感染性休克是重症医学研究的焦点和难点。临床工作中发现，感染性休克患者常伴有红细胞压积（hematocrit Hct）升高，血清白蛋白浓度（Serum albumin Alb）...感染性休克在重症患者中占有相当大的比率，也是重症病房主要死亡的原因。因此感染性休克是重症医学研究的焦点和难点。临床工作中发现，感染性休克患者常伴有红细胞压积（hematocrit Hct）升高，血清白蛋白浓度（Serum albumin Alb）降低，作者试图用二者之间的差值与急性生理与慢性健康评分（Acute physiology and chronic health evaluation II APACHE II）及病死率进行相关性分析，现报道如下。展开更多
Background/Aims: Insulin-like growth factor I (IGF-I) is an anabolic hormone synthesized in the liver whose levels decrease sharply in liver cirrhosis. Methods: We conducted a randomized double-blind placebo-controlle...Background/Aims: Insulin-like growth factor I (IGF-I) is an anabolic hormone synthesized in the liver whose levels decrease sharply in liver cirrhosis. Methods: We conducted a randomized double-blind placebo-controlled clinical trial to evaluate the effect of subcutaneous administration of IGF-I (20 μ g/kg/day with dose escalation to 50-100 μ g/kg/day) for 4 months in patients with alcoholic or primary biliary cirrhosis (PBC) and subnormal IGF-I levels. Eight alcoholics and one PBC entered the placebo group and seven alcoholics and two PBC the treatment group. Biochemistry, body composition, muscle mass and strength, and resting energy expenditure (REE) were evaluated. Results: Total serum IGF-I and IGF-I/IGFBP-3 ratio (a surrogate marker of IGFI biovailability) increased in the treatment group but IGF-I values still remained below normal limits in the treated patients. No differences were observed in body composition, muscle strength or muscle mass between groups. However, IGF-I therapy increased significantly serum albumin (P = 0.038) and this improvement correlated positively with variation of IGFI/ IGFBP-3 ratio. IGF-I treatment also tended to increase REE (P = 0.085); this difference was significant (P = 0.049) in the subgroup of alcoholic patients. Conclusions: A short course of IGF-I increased albumin levels and tended to improve energy metabolism in liver cirrhosis. These findings warrant larger clinical trials to assess the clinical benefit of IGF-I in cirrhotic patients.展开更多
文摘目的了解新生儿重症监护室(the neonatal in-tensive care unit,NICU)足月新生儿入院24h内血清白蛋白浓度改变情况与新生儿危重病例评分及预后的关系。方法测定71例足月新生儿入院24h内血清白蛋白浓度,把血清白蛋白浓度分为<35g/L、35～50g/L2组,分析血清白蛋白浓度与新生儿危重病例评分及预后的关系。结果血清白蛋白浓度异常与预后有关,血清白蛋白浓度<35g/L组新生儿危重病例评分比正常组低、死亡人数百分比比正常组高,住院时间长。结论低血清白蛋白浓度与足月新生儿的预后有重要相关性。
文摘感染性休克在重症患者中占有相当大的比率，也是重症病房主要死亡的原因。因此感染性休克是重症医学研究的焦点和难点。临床工作中发现，感染性休克患者常伴有红细胞压积（hematocrit Hct）升高，血清白蛋白浓度（Serum albumin Alb）降低，作者试图用二者之间的差值与急性生理与慢性健康评分（Acute physiology and chronic health evaluation II APACHE II）及病死率进行相关性分析，现报道如下。
文摘Background/Aims: Insulin-like growth factor I (IGF-I) is an anabolic hormone synthesized in the liver whose levels decrease sharply in liver cirrhosis. Methods: We conducted a randomized double-blind placebo-controlled clinical trial to evaluate the effect of subcutaneous administration of IGF-I (20 μ g/kg/day with dose escalation to 50-100 μ g/kg/day) for 4 months in patients with alcoholic or primary biliary cirrhosis (PBC) and subnormal IGF-I levels. Eight alcoholics and one PBC entered the placebo group and seven alcoholics and two PBC the treatment group. Biochemistry, body composition, muscle mass and strength, and resting energy expenditure (REE) were evaluated. Results: Total serum IGF-I and IGF-I/IGFBP-3 ratio (a surrogate marker of IGFI biovailability) increased in the treatment group but IGF-I values still remained below normal limits in the treated patients. No differences were observed in body composition, muscle strength or muscle mass between groups. However, IGF-I therapy increased significantly serum albumin (P = 0.038) and this improvement correlated positively with variation of IGFI/ IGFBP-3 ratio. IGF-I treatment also tended to increase REE (P = 0.085); this difference was significant (P = 0.049) in the subgroup of alcoholic patients. Conclusions: A short course of IGF-I increased albumin levels and tended to improve energy metabolism in liver cirrhosis. These findings warrant larger clinical trials to assess the clinical benefit of IGF-I in cirrhotic patients.
